Mast Therapeutics (MSTX) Tops Q2 EPS by 1c

Mast Therapeutics (NYSE: MSTX) reported Q2 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Utah Medical Products (UTMD) Reports Q1 EPS of $1.10
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance